Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCB-DM101 in Healthy Volunteers and T2DM Patients
NCT03033433Phase 1Completed
- Sponsor
- VitNovo
- Start
- Oct 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of DCB-DM101 in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by VitNovo. Primary endpoints: Optimal dose for Stage 2, dose limiting toxicity (DLT) at 7 months and Number of Participants with Adverse events and Serious adverse events that are related to treatment at 3 months. Started Oct 2016; status: completed.
02
Drugs
DCB-DM101
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03033433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03033433.